Pharmaceutical

Lilly's Cialis receives European approval for new use

October 30, 2012
Associated Press
The European Union has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
More

Lilly's insulin dip concerns analysts

October 29, 2012
J.K. Wall
Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.
More

Lilly continues string of positive trials

October 22, 2012
J.K. Wall
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
More

Lilly says experimental diabetes drug outperformed rivals

October 22, 2012
J.K. Wall
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
More

Alzheimer’s prevention seen promising as drug cures fail

October 19, 2012
Bloomberg News
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
More

Lilly stomach-cancer drug helps survival, study finds

October 15, 2012
Bloomberg News
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.
More

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

October 10, 2012
Bloomberg News
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
More

Lilly shares rise on Alzheimer's study results

October 8, 2012
J.K. Wall
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
More

Lilly counting on diabetes products to challenge larger rivals

October 8, 2012
Bloomberg News
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
More

Group aims to cut costs of late-stage drugs

September 24, 2012
J.K. Wall
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
More

Lilly's Cialis gets European endorsement for new use

September 21, 2012
Associated Press
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
More

Ten drugmakers team up to improve testing process

September 19, 2012
Associated Press
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
More

Two more clinical trials go against Lilly

September 4, 2012
J.K. Wall
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
More

Lilly stops testing of experimental schizophrenia drug

August 29, 2012
Bloomberg News
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
More

Lilly's Alzheimer's finding triggers investor hope, doctor caution

August 27, 2012
Bloomberg News
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More

Lilly wins appeal upholding patent for Alimta cancer drug

August 24, 2012
Bloomberg News
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
More

Lilly's Alzheimer's drug trials show mixed results

August 24, 2012
Bloomberg News, J.K. Wall
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
More

Lilly stock slips after competitors halt Alzheimer's plans

August 7, 2012
 IBJ Staff and Bloomberg News
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
More

Despite funding dip, IU bets on brains

August 6, 2012
J.K. Wall
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
More

McKesson to pay $151M to settle drug-pricing suit

July 27, 2012
Associated Press
Twenty-nine states, including Indiana, have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.
More

Lilly's quarterly profit falls, but tops analyst expectations

July 25, 2012
Bloomberg News
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
More

Potential Alzheimer’s drug fails first of four key trials

July 24, 2012
Bloomberg News
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
More

Potential Lilly antipsychotic falls short in study

July 11, 2012
Associated Press
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
More

Lilly gets 6-month Cymbalta marketing extension

July 6, 2012
Associated Press
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
More

Lilly cancer treatment fails trial in stomach cancer

July 5, 2012
 IBJ Staff and Bloomberg News
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT